LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Option Care Health To Participate in Upcoming Investor Conferences

August 25, 2025 | Last Trade: US$32.51 0.10 0.31

BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • Deutsche Bank Healthcare Summit, being held in New York City, from Wednesday, September 10, 2025 to Thursday, September 11, 2025.
  • Jefferies Healthcare Services Conference, being held in Nashville, on Tuesday, September 30, 2025, including a fireside chat at 1:15pm CT/2:15pm ET.

The webcast link for the Jefferies Healthcare Services Conference will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:

Nicole Maggio
Senior Vice President, Finance
T: (312) 940-2495
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page